Insiders Load Up on Pulse Biosciences
- By Kyle Ferguson
Insiders Robert Duggan, 10% owner, and Maky Zanganeh, director, recently bought shares of Pulse Biosciences Inc. (PLSE).
Duggan purchased a total 205,127 shares of the company between March 16 and March 18 in five transactions. Duggan purchased 73,782 shares of the company on March 16 in three transactions for an average price of $23.87 per share. He then added 25,859 shares on March 17 for $24.71 per share. His final purchase on March 18 consisted of an additional 105,486 shares for $23.09 per share.
Warning! GuruFocus has detected 2 Warning Sign with PLSE. Click here to check it out.
The intrinsic value of PLSE
Zanganeh purchased 18,240 shares of the company in four transactions in the month of March. In his first transaction, he purchased 8,960 shares for $23.97 per share on March 17 . He then added an additional 9,280 shares on March 20, .
In February, Duggan purchased 41,624 shares of the company on Feb. 9th for $11.64 per share. Zanganeh purchased 13,000 shares on Feb. 15 for $11.97 per share.
Following these purchases, Duggan now owns a total of 2.4 million shares and Zanganeh owns 310,649 shares.
Headquartered in Burlingame, California, Pulse Biosciences is a development stage medical device company. It has a proprietary platform technology called Nano-Pulse Electro-Signaling (NPES) used for biomedical applications to detect and treat skin cancer and enhance wound healing.
The company was was formerly known as Electroblate Inc. and changed its name to Pulse Biosciences in December 2015.
Pulse Biosciencs has a market cap of $306.68 million, an enterprise value of $287.99 million, a price-book (P/B) ratio of 12.10, a price-to-net cash ratio of 19.85 and a quick ratio of 19.66.
According to GuruFocus, Pulse has a 7 of 10 financial strength rating with no debt. The company has an Altman Z-Score of 204.57, indicating it has a healthy financial condition.
The company has a 2 of 10 profitability and growth rating. It has a return on equity (ROE) of -43.47%, a return on assets (ROA) of -41.99% and a return on capital (ROC) of -2889.09%.
Pulse Biosciences has recently had an upswing in price. Since Feb. 28, the company's market price has gone from $13.44 per share to $25.09 per share, rising an estimated 86.68%.
Disclosure: Author does not own any shares of this company.
Start a free 7-day trial of Premium Membership to GuruFocus.
This article first appeared on GuruFocus.
Warning! GuruFocus has detected 2 Warning Sign with PLSE. Click here to check it out.
The intrinsic value of PLSE
